Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer - A Multicenter Retrospective Longitudinal Study

Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer - A Multicenter Retrospective Longitudinal Study - QA-CXmet 2018 – 2022

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031409

Enrollment

300

Registered

2023-06-01

Start date

2023-06-26

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Cervical Cancer C53

Interventions

Group 1: Observation of routine clinical care of patients with metastatic cervical cancer

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Histologically proven diagnosis of cervical cancer Diagnosis FIGO Stage IVB or relapsed metastatic disease between 2018 and 2022

Exclusion criteria

Exclusion criteria: FIGO stage IA1-IVA Non-squamous or Non-adenocarcinoma histology (e.g. neuroendocrine tumors, sarcoma, lymphoma)

Design outcomes

Primary

Measure	Time frame
The main target criterion is the degree of implementation of the guideline recommendations in the choice of primary systemic treatment: The guideline recommendation includes platinum-containing combination therapy, maintenance therapy with bevacizumab, and the addition of pembrolizumab when appropriate in patients with a CPS>1	—

Secondary

Measure	Time frame
Progression Free Survival (PFS) Overall Survival (OS) Subsequent Therapies	—

Countries

Germany

Contacts

Public ContactMarkus Kerkmann

MMF GmbH

cxmet@mmf-research.de+49 251 928 730 00

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026